Trial Profile
A Phase IIIb Randomized Open-label Study to Compare the Estradiol Level on the Releasing Day in Two Regimen of Cetrotide 0.25 mg Used From Day 1 or From Day 7 of the Menstrual Cycle (Day 0 or Day 6 of Stimulation) in Polycystic Ovarian (PCO) Women in ART (IVF/ICSI).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Cetrorelix (Primary) ; Choriogonadotropin alfa
- Indications Female infertility; Polycystic ovary syndrome
- Focus Pharmacodynamics
- Acronyms ATTAC-PCO
- Sponsors Merck Lipha Sante
- 02 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2011 Planned end date changed from 1 Sep 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 04 Sep 2010 New trial record